Madison Dearborn Partners to acquire Alcami

Alcami Corporation, a leading provider of fully-integrated custom end-to-end solutions for the pharmaceutical and biotechnology industries, has reached an agreement to be acquired by Madison Dearborn Partners (MDP), a leading private equity firm based in Chicago. MDP will acquire a majority ownership position in Alcami from existing shareholder Ares Capital Corporation. 

The transaction is expected to be completed in the third quarter of 2018, pending customary closing conditions.

“The entire Alcami team is excited to further enhance and evolve the small to mid-size pharma growth engine. As we enter our next stage of progress as a leading global, clinically-focused and fully-integrated contract development and manufacturing organization (CDMO), we are proud to partner with MDP to expand our talented employee base and further develop our capabilities. There’s no doubt we will continue to serve our clients with dedication, innovative solutions, and our unique, flexible, transparent, and proactive approach,” said CEO, president and chairman, Dr Stephan Kutzer. 

“MDP’s extensive experience and strong relationships in the health care and life sciences sectors make them an ideal partner. Looking forward, we will continue to be guided by prioritising efficient, rapid, and reliable development, while delivering the highest quality and best customer experience in the industry.”

Headquartered within Research Triangle Park (RTP) in Durham, North Carolina, US – and with 10 locations across the globe – Alcami is a world-class CDMO and the first company to provide a solution tailored to small and mid-size pharmaceutical and biotechnology companies. It provides fully-integrated end-to-end outsourcing opportunities, which offer a faster pathway for products through the clinic toward commercialisation, as well as individualised development and manufacturing services. 

Alcami’s services include API development and manufacturing, solid state chemistry, formulation development, analytical development and testing services, drug product manufacturing (oral solid dose and parenteral), and packaging and stability services.